| Effects of rosiglitazone and pioglitazone on lipoprotein metabolism in patients with Type 2 diabetes and normal lipids. | |
| | |
MedLine Citation:
|
PMID: 19646194 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
AIMS: Previous studies have suggested that plasma lipids are affected differently by the peroxisome proliferators-activated receptor (PPAR)-gamma agonists pioglitazone and rosiglitazone. The aim of this study was to perform a quantitative lipoprotein turnover study to determine the effects of PPAR-gamma agonists on lipoprotein metabolism. METHODS: Twenty-four subjects with Type 2 diabetes treated with diet and/or metformin were randomized in a double-blind study to receive 30 mg pioglitazone, 8 mg rosiglitazone or placebo once daily for 3 months. Before and after treatment, absolute secretion rate (ASR) and fractional catabolic rate (FCR) of very low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL) and low-density lipoprotein (LDL) apolipoprotein B100 were measured with a 10-h infusion of 1-13C leucine. RESULTS: There was a significant decrease in glycated haemoglobin (HbA(1c)) and non-esterified fatty acids with pioglitazone (P = 0.01; P = 0.02) and rosiglitazone (P = 0.04; P = 0.003), respectively, but no change in plasma triglyceride or high-density lipoprotein (HDL) cholesterol. Following rosiglitazone, there was a significant reduction in VLDL apolipoprotein B100 (apoB) ASR (P = 0.01) compared with baseline, a decrease in VLDL triglyceride/apoB (P = 0.01), an increase in LDL2 cholesterol (P = 0.02) and a decrease in LDL3 cholesterol (P = 0.02). There was a decrease in VLDL triglyceride/apoB (P = 0.04) in the pioglitazone group. There was no significant difference in change in VLDL ASR or FCR among the three groups. CONCLUSIONS: In patients with Type 2 diabetes and normal lipids, treatment with rosiglitazone or pioglitazone had no significant effect on lipoprotein metabolism compared with placebo. |
| | |
Authors:
|
A L Brackenridge; N Jackson; W Jefferson; M Stolinski; F Shojaee-Moradie; R Hovorka; A M Umpleby; D Russell-Jones |
Related Documents
:
|
7665994 - Impact of age on the metabolism of vldl, idl, and ldl apolipoprotein b-100 in men. 3714724 - Oral nicotine induces an atherogenic lipoprotein profile. 20167214 - Identification and properties of complexes formed by myeloperoxidase with lipoproteins ... 6717274 - Lipid metabolism in nephrotic rats induced by daunomycin injection. 14967814 - Increased production of vldl apob-100 in subjects with familial hypercholesterolemia ca... 19568314 - Bioassay design and length of time in the laboratory affect intercolonial interactions ... |
Publication Detail:
|
Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Diabetic medicine : a journal of the British Diabetic Association Volume: 26 ISSN: 1464-5491 ISO Abbreviation: Diabet. Med. Publication Date: 2009 May |
Date Detail:
|
Created Date: 2009-08-03 Completed Date: 2010-02-22 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8500858 Medline TA: Diabet Med Country: England |
Other Details:
|
Languages: eng Pagination: 532-9 Citation Subset: IM |
Affiliation:
|
Centre for Diabetes, Endocrinology and Research, Royal Surrey County Hospital, Guildford, Surrey GU2 7XX, UK. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Diabetes Mellitus, Type 2 / drug therapy, metabolism* Female Hemoglobin A, Glycosylated / drug effects Humans Hypoglycemic Agents / therapeutic use* Lipoproteins / drug effects*, metabolism Male Middle Aged Placebos Statistics, Nonparametric Thiazolidinediones / therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Hemoglobin A, Glycosylated; 0/Hypoglycemic Agents; 0/Lipoproteins; 0/Placebos; 0/Thiazolidinediones; 111025-46-8/pioglitazone; 122320-73-4/rosiglitazone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Effects of grape seed extract in Type 2 diabetic subjects at high cardiovascular risk: a double blin...
Next Document: Randomized controlled trial to assess the impact of continuous glucose monitoring on HbA in insulin-...